HSBC Holdings’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21K Buy
+16,660
New +$19.5K ﹤0.01% 2859
2026
Q2
– Sell
-10,577
Closed -$40K – 2915
2026
Q1
$40K Buy
10,577
+56
+0.5% +$221 ﹤0.01% 2822
2025
Q4
$37.7K Hold
10,521
– – ﹤0.01% 2880
2025
Q3
$41.6K Buy
+10,521
New +$33.2K ﹤0.01% 2653

Other funds holding ADCT

HSBC Holdings's ADCT Position: Q3 2026 in Review

HSBC Holdings opened a new position in ADC Therapeutics (ADCT) in Q3 2026: 16,660 shares worth $21K. The stake represents ﹤0.01% of the portfolio and ranks #2859 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in ADCT as recently as Q1 2026.

HSBC Holdings first reported a position in ADCT in Q3 2025 and has held it in 4 quarters since. The position peaked at $41.6K in Q3 2025. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • HSBC Holdings held 16,660 shares of ADC Therapeutics worth $21K as of Q3 2026.
  • ADC Therapeutics was a new HSBC Holdings position in Q3 2026.
  • ADC Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q3 2026, its #2859 holding.
  • HSBC Holdings first reported a position in ADC Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • HSBC Holdings's ADC Therapeutics position peaked at $41.6K in Q3 2025.
  • 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.